Diabetes technology company Tandem Diabetes Care (NASDAQ: TNDM) will be reporting earnings this Thursday afternoon. Here’s what investors should know.

Tandem Diabetes met analysts’ revenue expectations last quarter, reporting revenues of $254.6 million, up 5.8% year on year. It was a mixed quarter for the company, with EPS in line with analysts’ estimates but full-year revenue guidance meeting analysts’ expectations.

Is Tandem Diabetes a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Tandem Diabetes’s revenue to grow 5.8% year on year, improving from the 2.6% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Tandem Diabetes has a history of exceeding Wall Street’s expectations.

Looking at Tandem Diabetes’s peers in the healthcare technology segment, only Omnicell has reported results so far. It exceeded analysts’ revenue estimates and delivered flat year-on-year revenue. The stock traded up 1.9% on the results.

There has been positive sentiment among investors in the healthcare technology segment, with share prices up 2.8% on average over the last month. Tandem Diabetes is up 6.9% during the same time and is heading into earnings with an average analyst price target of $27.76 (compared to the current share price of $17.66).

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.